Release 4

This page is part of the FHIR Specification (v4.0.1: R4 - Mixed Normative and STU) in it's permanent home (it will always be available at this URL). The current version which supercedes this version is 5.0.0. For a full list of available versions, see the Directory of published versions . Page versions: R4 R3

4.4.2.1070 HL7 v3 Code System substanceAdminSubstitution

Vocabulary Work Group Maturity Level: N/A External Use Context: Any

This code system (http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution) is defined as part of HL7 v3.

Summary

Defining URL: http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution

Version: 2018年08月12日

Name: v3.substanceAdminSubstitution

Title: v3 Code System substanceAdminSubstitution

Definition:

Identifies what sort of change is permitted or has occurred between the therapy that was ordered and the therapy that was/will be provided.

OID: 2.16.840.1.113883.5.1070 (for OID based terminology systems)

Source Resource XML / JSON

This Code system is used in the following value sets:

ValueSet: v3 Code System substanceAdminSubstitution ( Identifies what sort of change is permitted or has occurred between the therapy that was ordered and the therapy that was/will be provided.)
ValueSet: V3 Value SetActSubstanceAdminSubstitutionCode (No Description Provided)

4.4.2.1070.1 Code System Content

Release Date: 2018年08月12日

Level Code Display Definition

1 (_ActSubstanceAdminSubstitutionCode) Abstract Description: Substitution occurred or is permitted with another product that may potentially have different ingredients, but having the same biological and therapeutic effects.

2 E equivalent Description: Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product.

3 EC equivalent composition Description:
Substitution occurred or is permitted with another product that is a:
pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration Examples:
Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin Stearate Pharmaceutical equivalent: Lisonpril for Zestril

4 BC brand composition Description:
Substitution occurred or is permitted between equivalent Brands but not Generics
Examples:
Zestril for Prinivil Coumadin for Jantoven

4 G generic composition Description: Substitution occurred or is permitted between equivalent Generics but not Brands
Examples:
Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp)

3 TE therapeutic alternative Description: Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile.
Examples:
ranitidine for Tagamet

4 TB therapeutic brand Description: Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics
> Examples:
Zantac for Tagamet

4 TG therapeutic generic Description: Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands
> Examples:
Ranitidine for cimetidine

2 F formulary Description: This substitution was performed or is permitted based on formulary guidelines.

2 N none No substitution occurred or is permitted.